Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)

Trial Profile

A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emrusolmin (Primary)
  • Indications Multiple system atrophy
  • Focus Therapeutic Use
  • Acronyms TOPAS-MSA
  • Sponsors Teva Branded Pharmaceutical Products R&D

Most Recent Events

  • 02 Nov 2026 An interim results were presented in a Teva Pharmaceutical Industries media release.
  • 02 Nov 2026 According to Teva Pharmaceutical Industries media release, the company announced that it will work with the investigators to ensure the study protocols are followed while the study is discontinued. The company plans to share the findings with the scientific community following completion of its comprehensive analysis.
  • 02 Nov 2026 Status changed from active, no longer recruiting to discontinued, the decision follows a recommendation from the independent data monitoring committee (IDMC), based on interim futility analysis, which indicated a low likelihood of meeting the primary efficacy endpoint. No safety concerns were identified.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top